Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis.
Diabetes Metab Syndr
; 15(5): 102210, 2021.
Article
in English
| MEDLINE | ID: covidwho-1313054
ABSTRACT
AIMS:
This meta-analysis aims to analyze the association of calcium channel blocker (CCB) use with COVID-19 clinical outcomes.METHODS:
PubMed, ProQuest, Science Direct, Scopus, and medRxiv databases were searched systematically in a limited period. The primary outcome was mortality.RESULTS:
A total of 119,298 patients from 31 eligible studies were included. Pooled analysis of the random-effect model revealed CCB was not associated with reduced mortality (OR = 1.21 [95%CI 0.98-1.49], p = 0.08). Interestingly, subgroup analysis in hypertensive patients revealed significantly reduced mortality (OR = 0.69 [95%CI 0.52-0.91], p = 0.009).CONCLUSION:
CCB usage was not associated with the outcome of COVID-19. However, CCB was associated with a decreased mortality rate in hypertensive COVID-19 patients.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Calcium Channel Blockers
/
COVID-19
Type of study:
Diagnostic study
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Diabetes Metab Syndr
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS